Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B.
Mar S, et al. Among authors: shen ya.
J Neurol. 2025 Jan 15;272(2):137. doi: 10.1007/s00415-024-12879-z.
J Neurol. 2025.
PMID: 39812825